Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

[1]  R. Collins,et al.  Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. , 2007, American heart journal.

[2]  M. Garzotto,et al.  Statins and prostate cancer risk: a case-control study. , 2005, American journal of epidemiology.

[3]  Ronit Almog,et al.  Statins and the risk of colorectal cancer. , 2005, The New England journal of medicine.

[4]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[5]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[6]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[7]  E. Braunwald,et al.  General cardiology: abstractComparison of intensive and moderate lipid lowering with statins after acute coronary syndromes , 2004 .

[8]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[9]  M. Law,et al.  Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies , 1991, Cancer Causes & Control.

[10]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.

[12]  J. Tobert,et al.  Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors , 2003, Nature Reviews Drug Discovery.

[13]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[14]  I. Holme,et al.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial , 2003, The Lancet.

[15]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[16]  P. Thompson,et al.  Statin-associated myopathy. , 2003, JAMA.

[17]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[18]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[19]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[20]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[21]  K. Tolman.  The liver and lovastatin. , 2002, The American journal of cardiology.

[22]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[23]  M. Ezekowitz,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[24]  N. Furutani,et al.  [WOSCOPS [West of Scotland Coronary Prevention Study]]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[25]  Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.

[26]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[27]  O. Faergeman,et al.  Effect of greater LDL-C reductions on prognosis-the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial , 1999 .

[28]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[29]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[30]  G. Assmann,et al.  Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? , 1997, The American journal of cardiology.

[31]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[32]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[33]  M. Pfeffer,et al.  Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. , 1995, The American journal of cardiology.

[34]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[35]  B. Psaty,et al.  The Association between Cholesterol and Death from Injury , 1994, Annals of Internal Medicine.

[36]  M. Law,et al.  Assessing possible hazards of reducing serum cholesterol , 1994, BMJ.

[37]  N J Wald,et al.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.

[38]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[39]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[40]  G. Davey Smith,et al.  Should there be a moratorium on the use of cholesterol lowering drugs? , 1992, BMJ.

[41]  R Peto,et al.  Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.

[42]  M. Oliver.  Might treatment of hypercholesterolaemia increase non-cardiac mortality? , 1991, The Lancet.

[43]  B. Rifkind,et al.  The value of lowering cholesterol after myocardial infarction. , 1990, The New England journal of medicine.

[44]  K. Matthews,et al.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.

[45]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[46]  C. E. Becker.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[47]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[48]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .